Literature DB >> 7847801

High expression of the EGFR in fibroadenomas compared to breast carcinomas.

M Zelada-Hedman1, G Werer, P Collins, M Bäckdahl, I Perez, S Franco, J Jimenez, J Cruz, M Torroella, M Nordenskjöld.   

Abstract

The epidermal growth factor receptor and its ligands have been implicated as being involved in normal mammary development and breast cancer genesis. Northern blotting was used to assay the mRNA levels of the epidermal growth factor receptor and three of its ligands: the epidermal growth factor, the transforming growth factor alpha and the Amphiregulin in 16 primary carcinomas, 2 metastases and 5 fibroadenomas. In addition, the mRNA levels of the other members of the epidermal growth factor receptor family, erbB2 and erbB3 were also analysed. We found limited expression in the breast carcinomas while all the fibroadenomas showed expression at high levels. Therefore we suggest that the epidermal growth factor receptor plays an important role in the development of fibroadenomas. The erbB2 and erbB3 were more strongly expressed than the epidermal growth factor receptor in the primary carcinomas. This suggests that they could be of importance in breast carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7847801

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  The epidermal growth factor receptor in breast cancer.

Authors:  S B Fox; A L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Abnormal regulation of the oestrogen receptor in benign breast lesions.

Authors:  B S Shoker; C Jarvis; R B Clarke; E Anderson; C Munro; M P Davies; D R Sibson; J P Sloane
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

3.  A flow cytometric study of c-erbB-3 expression in breast cancer.

Authors:  I Brotherick; B K Shenton; B Angus; I S Waite; C H Horne; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.